The Trendlines Group Ltd.
Other OTCRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- The Trendlines Group Ltd. (SGX: 42T; OTCQX: TRNLY) serves as an Israel-based innovation commercialization company and private equity firm that invests in, incubates, and develops early-stage companies in medical technologies and agrifood technologies; its core activities encompass technology development, business building, R&D support, commercialization strategies, funding facilitation, and market access for portfolio firms across sectors including cardiology, neurology, urology, women's health, surgery, spine and orthopedics, crop protection, aquaculture, digitization, robotics, future foods, and net-zero technologies. The company operates through business units such as Trendlines Medical, Trendlines Agtech, Trendlines Medical Singapore, and Trendlines Labs, maintaining a portfolio exceeding 50 companies with select examples featuring devices for clot extraction in ischemic stroke, stress urinary incontinence alleviation, pelvic organ prolapse repair, bioactive coral-based bone grafts, phage-based crop protection solutions, natural food colors from yeast fermentation, AI-driven crop disease analytics, and cell-cultured cocoa ingredients; it provides hands-on services like business development, financial support, and marketing to entrepreneurs targeting global markets in healthcare and agriculture. Founded in 2007 and headquartered at 17 T'chelet Street, Misgav Business Park, Israel, with additional offices in Singapore, Tel Aviv, and formerly Beijing, the group leverages partnerships with investors, governments, and strategic players including Israel Innovation Authority grants to advance its mission of improving the human condition through seed-to-market progression. Recent developments include portfolio firm IBI Ag securing $6.1 million in Series A funding led by Corteva in 2025 with Trendlines participation, Arcuro Medical closing initial Series A led by Varana Capital involving Trendlines, EIC Fund co-financing for a women's health solution in June 2025, Phytolon achieving manufacturing efficiency milestones in May 2025, September 2025 strategic partnerships such as SOLVEAT-CBC alongside SEGER's FDA progress, Celleste Bio's cell-cultured cocoa butter milestone, and the cessation of CFO Igor Vatenmacher effective November 13, 2025; these activities alongside ongoing investments by Trendlines and Librae Holdings underscore portfolio momentum in regulatory approvals, capital raises, and technological advancements.
2 Trendlines in Focus For Pfizer Stock After Earnings
IBI Ag Announces Successful Development of AI-Driven De Novo Protein Design Platform for Bioinsecticides
Key Trendlines to Watch After S&P 500's New Records
Natural Gas and Oil Forecast: Rally Extends, but Descending Trendlines Cap Upside Potential
S&P 500 Trendlines to Watch as Bulls Remain in Control
IBI Ag Completes $10 Million Series A Round Led by Corteva
Natural Gas and Oil Forecast: OPEC+ Hike and Trendlines Signal Further Weakness
Escala Secures $4.5M in Funding to Accelerate Global Expansion of Its FDA-Approved Medical Device
Why Nvidia Stock Woos Investors With Trendlines, Not Headlines
Natural Gas and Oil Forecast: Trendlines Hold as Traders Eye $3.76 and $63.86
Sprouts Farmers Market Stock Nears 2 Bullish Trendlines
3 Resistance Trendlines Driving the S&P 500's Advance
Arcuro Medical Announces FDA 510(k) Clearance for the SuperBall RC for Rotator Cuff Indications
Limaca's Precision-GI™ Enters US Market
IBI Ag Secures $6.1 Million in Funding Round Led by Corteva Inc.
Varana Capital Leads Arcuro Medical's Series A Financing, Driving Strategic Growth in 2025
GE Aerospace Stock Could Bounce Off Bullish Trendlines
Limaca's Precision-GI™ Granted CMS Transitional Pass-Through (TPT) Payment
Vensica Medical Secures $11M in Funding to Support Phase 2 Trials for Overactive Bladder Treatment
ElastiMed Welcomes Dr. Amir Belson as a Member of the Board of Directors